Searchable abstracts of presentations at key conferences in endocrinology

ea0090p598 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Impact of Setmelanotide Treatment on Weight- and Body Composition–Related Outcomes in Pediatric and Adult Patients With Hypothalamic Obesity

Miller Jennifer , Shoemaker Ashley H. , Jennifer Abuzzahab M. , Gottschalk Michael , Yuan Guojun , Malhotra Sonali , Scimia Cecilia , Roth Christian L.

Background: Hypothalamic obesity (HO) is an acquired form of severe obesity that can occur following surgical resection of or radiotherapy for brain tumors and is often unresponsive to lifestyle modifications or traditional obesity pharmacotherapies. Here, we report weight- and body composition–related findings from a Phase 2 trial of setmelanotide, a melanocortin-4 receptor agonist, in patients with HO.Methods: A Phase 2, open-label, 16-week trial ...

ea0090p134 | Pituitary and Neuroendocrinology | ECE2023

Efficacy and Safety Analysis of Setmelanotide As a Novel Treatment for Hypothalamic Obesity

Roth Christian L. , Shoemaker Ashley H. , Gottschalk Michael , Miller Jennifer L. , Yuan Guojun , Chen Evan , Scimia Cecilia , Jennifer Abuzzahab M.

Background: Hypothalamic injury and impaired melanocortin-4 receptor (MC4R) pathway signaling, often a result of surgery or radiation for a benign tumor, may lead to hypothalamic obesity (HO). After injury, sudden weight gain and appetite changes unresponsive to existing therapies develop. Setmelanotide, an MC4R agonist, is approved for chronic weight management in patients with certain MC4R pathway–associated diseases. We report interim results of a Phase 2 study of setm...

ea0090p680 | Pituitary and Neuroendocrinology | ECE2023

Impact of Setmelanotide Treatment on Reducing Hyperphagia in Pediatric and Adult Patients With Hypothalamic Obesity

Roth Christian L. , Shoemaker Ashley H. , Gottschalk Michael , Miller Jennifer , Yuan Guojun , Malhotra Sonali , Scimia Cecilia , Jennifer Abuzzahab M.

Objective: To report hunger-related results from a Phase 2 trial of setmelanotide in patients with hypothalamic obesity (HO).Methods: A Phase 2, open-label, 16-week trial of setmelanotide in patients aged ≥6 to ≤ 40 years with body mass index (BMI) ≥95th percentile (aged <18 years) or ≥35 kg/m2 (aged ≥18 years) and HO caused by hypothalamic damage secondary to brain tumor, surgical resection, and/or chemothera...

ea0025p244 | Pituitary | SFEBES2011

BAC recombineering to understand the role of the alternative promoter in the regulation of prolactin expression

Awais Raheela , McNamara Anne , Harper Claire , Adamson Anthony , Spiller Dave , Semprini Sabrina , Mullins John , Davis Julian , White Michael R H

Alternative promoters control many genes including prolactin (PRL), which in man is expressed at extra-pituitary sites controlled by an alternative promoter located 5.8 Kbp upstream of the pituitary transcription start site. Previous studies using short promoter fragments may be misleading, as the human hPRL genomic locus has many conserved far-upstream regions. To study the function of the alternative promoter, we engineered a bacterial artificial chromosome (BAC) expressing ...

ea0022p713 | Obesity | ECE2010

Gastric inhibitory polypeptide (GIP) suppresses circulating ghrelin in humans: plasma metabolome based correlation network analysis for support of hormone-to- hormone interactions

Rudovich Natalia , Nikiforova Victoria J , Otto Baerbel , Pivovarova Olga , Gogebakan Ozlem , Weickert Martin O , Nauck Michael A , Pfeiffer Andreas F H

Aims: We investigate the influence of GIP on ghrelin secretion in normal glucose tolerant individuals with the use of the firstly applied correlation network analysis on human plasma metabolome data.Methods: To address this issue, we employed a GIP-infusion test and euglycemic- and hyperglycemic glucose clamp experiments combined with infusion of GIP or placebo in a cross-over manner in non diabetic obese male subjects (n=14). Moreover, we firstly...

ea0020p229 | Bone/Calcium | ECE2009

Swiss primary hyperparathyroidism cohort study

Trombetti Andrea , Meier Christian , Kraenzlin Marius E , Herrmann Francois R , Henzen Christoph H , Christ Emmanuel R , Brandle Michael , Rizzoli Rene

Objective: The Swiss Primary HyperParaThyroidism (PHPT) Cohort Study is an ongoing, prospective, non-interventional project collecting clinical, densitometric, biochemical and outcome data in patients with PHPT. The aims are to describe the profile of these patients particularly neurobehavioral and cognitive symptoms, changes in calcium and PTH over time and treatment modalities.Methods: Patients newly diagnosed with PHPT and with high serum calcium leve...

ea0016p515 | Obesity | ECE2008

Glucose-dependent insulinotropic polypeptide (GIP) receptor knock-out prevents ovariectomy-induced obesity in mice

Isken Frank , Pfeiffer Andreas FH , Nogueiras Ruben , Osterhoff Martin A , Ristow Michael , Thorens Bernard , Tschop Matthias H , Weickert Martin O

Objectives: Premature estrogen deficiency and menopause are associated with increases in body weight and fat mass. Ovariectomized (OVX) mice also show reduced locomotor activity. Because glucose-dependent-insulinotropic-polypeptide (GIP) is known to play an important role both in fat metabolism and locomotor activity, we hypothesized that effects of estrogen on the regulation of body weight, fat mass and spontaneous physical activity could be mediated in part by GIP signaling....

ea0098o3 | Other | NANETS2023

Clinical characteristics of mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN): a single institution case series

Storandt Michael H. , Cowan Annie N. , Hubbard Joleen M. , Halfdanarson Thorvardur R. , Eun Lee Hee , Jin Zhaohui

Background: Gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN) is a rare entity consisting of two morphologically distinct populations of cells, one of which is neuroendocrine and one which is non-neuroendocrine. MiNENs typically contain high grade neuroendocrine carcinoma, conferring a poor prognosis. Due to the rarity of this diagnosis, data is limited and therefore, we sought to add to the current clinical understanding of this diagnosis.<p ...

ea0015p296 | Reproduction | SFEBES2008

Hormonal regulation of 11β-hydroxysteroid dehydrogenase (11βHSD) enzyme activities in boar test is and caput epididymidis

Sharp Victoria , Michael Tony , Fowkes Rob

Cortisol is metabolised by two 11βHSD isoenzymes. Recently, we reported that 11βHSD1 and 11βHSD2 mRNA and protein are co-expressed in boar testis and throughout the male reproductive tract. However, enzyme activities were only detectable in boar testis, caput epididymidis, bulbourethral glands and penile urethra. The objective of the present study was to assess whether cortisol–cortisone metabolism in the boar testis and caput epididymidis could be regulate...

ea0029p989 | Growth hormone IGF axis - basic | ICEECE2012

Ghrelin suppresses angiotensin II-induced tissue damages by reducing oxidative stress

Fujimura K. , Wakino S. , Minakuchi H. , Tokuyama H. , Hayashi K. , Itoh H.

Objectives: Angiotensin II (AngII) induces renal premature senescence by multiple mechanisms including by increasing oxidative stress. Recent study revealed that growth hormone secretagogue ghrelin exerts anti-senescence effects. In this study, we examined whether ghrelin inhibits AngII-induced renal senescence and damages.Methods: Renal senescence was induced by infusion of Ang II in C57BL/6 mice with osmotic mini-pump. Ghrelin was administered by the d...